Trial of Canadian Ebola drug stopped after no overall benefit shown

Well, this is disappointing. Not only would I have liked to see it succeed because such a drug is needed, but also because it would help promote Canadian research. Nonetheless, a null result is still a result, and that is how science works.

Dr. Peter Horby, the chief investigator of the trial, says the drug has not been shown to benefit patients.

Horby says data from the trial still need to be analyzed.